Anzeige
Mehr »
Dienstag, 11.08.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40P4W | ISIN: SE0023261532 | Ticker-Symbol: PGO0
Frankfurt
11.08.26 | 15:25
0,007 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
PROSTATYPE GENOMICS AB Chart 1 Jahr
5-Tage-Chart
PROSTATYPE GENOMICS AB 5-Tage-Chart

Aktuelle News zur PROSTATYPE GENOMICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:59New equity right for trading, Prostatype Genomics AB51At the request of Prostatype Genomics AB, equity rights will be traded on First North Growth Market as from 12 August 2026. Security name: Prostatype Genomics AB...
► Artikel lesen
04.08.New last trading day for paid subscription shares (BTA) of Prostatype Genomics AB108At the request of Prostatype Genomics AB, the last trading day in Prostatype Genomics AB's paid subscription shares will be changed from 2026-08-10 to 2026-08-06. Instrument: Paid subscription...
► Artikel lesen
PROSTATYPE GENOMICS Aktie jetzt für 0€ handeln
27.07.Prostatype Genomics AB: Prostatype Genomics AB announces outcome in rights issue of units130NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA...
► Artikel lesen
21.07.Prostatype Genomics AB: Last day for subscription in Prostatype Genomics AB's rights issue of units is July 23, 2026182NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA...
► Artikel lesen
09.07.Prostatype Genomics AB: The subscription period in Prostatype Genomics AB's rights issue of units begins today190NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA...
► Artikel lesen
08.07.Listing of units rights and paid subscription units of Prostatype Genomics AB253With effect from July 09, 2026, the units rights in Prostatype Genomics AB will be traded on First North Growth Market. Trading will continue up until and including July 20, 2026. ...
► Artikel lesen
03.07.XFRA CAPITAL ADJUSTMENT INFORMATION - 03.07.20261.044Das Instrument OCI US00089H1068 ACS A.DE C.ADR 1/5/EO-,50 EQUITY wird cum Kapitalmassnahme gehandelt am 03.07.2026 und ex Kapitalmassnahme am 06.07.2026 The instrument OCI US00089H1068 ACS A.DE C.ADR...
► Artikel lesen
22.06.Prostatype Genomics AB: Bulletin From Annual General Meeting In Prostatype Genomics AB (publ)139The annual general meeting in Prostatype Genomics AB (publ), corp. reg. no 556726-0285 (the "Company") was held on 22 June 2026. Below is a summary of the resolutions adopted. All resolutions were adopted...
► Artikel lesen
25.05.Prostatype Genomics AB: Update from Prostatype Genomics Regarding the Medicare Reimbursement Process for Prostatype in the United States366Prostatype Genomics has been actively engaged in the process regarding Medicare reimbursement for Prostatype® in the United States for some time. The process is currently in an intensive phase and continues...
► Artikel lesen
19.05.Prostatype Genomics AB: Prostatype Genomics AB announces the Board of Directors' intention to resolve on a rights issue of units of approximately SEK 47.4 million246NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA...
► Artikel lesen
26.02.Prostatype Genomics AB: Prostatype Genomics publishes year-end report for 2025394Prostatype Genomics AB today publishes its year-end report for the full year 2025, including the interim report for the second half of 2025. The full year-end report is attached and can also be downloaded...
► Artikel lesen
11.11.25Prostatype Genomics AB: Previous Investments in Research and Development Unlock Hidden Assets in Prostatype Genomics364Alongside Prostatype Genomics (the "Company") strategic focus on the U.S. market and continued efforts to secure Medicare reimbursement, the Company has continuously invested in research and development...
► Artikel lesen
26.08.25Prostatype Genomics AB: Prostatype Genomics reaches important commercial breakthrough by initiating billing for Prostatype to insurance companies in the USA297Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has reached an important commercial milestone in the USA by immediately starting to bill Prostatype® to several insurance companies. Prostatype®...
► Artikel lesen
13 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1